Kyntra Bio

Antibody therapeutics (formerly FibroGen); roxadustat/Evrenzo retained

KYNB · Nasdaq · United States

Share price · KYNB

$1.95-5.06 (-72.18%) 3M

close as of 2026-11-18 · 24h delayed · vol 83K (2.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when KYNB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026-36.3%
  2. 10 Nov 2026-8.5%
  3. 4 Nov 2026-8.1%
  4. 23 Oct 2026-12.3%
  5. 19 Oct 2026+8.9%
  6. 16 Oct 2026-9.5%
  7. 15 Oct 2026-3.7%
  8. 14 Oct 2026-5.2%
  9. 17 Sep 2026-6.7%
  10. 2 Sep 2026+7.3%

Share of unusual movement by asset

For each asset, the share of KYNB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
FOR46
events and moves
5shown from 8 days
Roxadustat (Evrenzo)
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—11%
Other company news (earnings, financing, releases naming no asset)—24%
Sessions with no dated event—65%

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Roxadustat(Evrenzo)
Phase 3
HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule
Chronic Kidney DiseaseMyelodysplastic Syndromes
Phase 1
CD46Antibody–drug conjugate
Multiple Myeloma

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
Roxadustat · EvrenzoPhase 3Chronic Kidney Disease, Renal Anemia
Est. primary completion 2027-10-30 · NCT05970172 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
FOR46Phase 2Metastatic Castration-Resistant Prostate Cancer
Est. primary completion 2028-03-31 · NCT06842498 · CT.gov ↗
What to watch
2030 (1)
September 2030 (1)
Roxadustat · EvrenzoPhase 3Myelodysplastic Syndromes
Est. primary completion 2030-09 · NCT07722988 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 November 2026Topline resultFOR46Phase 2 interim analysis in mCRPC below the efficacy threshold; development discontinued
11 August 2021Complete response letterRoxadustatFDA issues complete response letter for the roxadustat NDA (anemia of CKD)
US, FDA · FibroGen · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2-$1.5M$6.8M$51M+ $41M short-term inv.—-$4.0M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$3.7M$7.6M$37M+ $50M short-term inv.$15M-$14M operating cash flowreport ↗
2025-Q3$1.1M$1.2M$118M—-$1.9M operating cash flowreport ↗
2025-Q2$1.4M$5.9M$23M$7.6M$13M operating cash flowreport ↗
2025-Q1$2.7M$9.2M$34M—$2.7M operating cash flowreport ↗
2024-Q3$46M$22M$131M+ $0 short-term inv.$17M-$8.4M operating cash flowreport ↗
2024-Q2$51M$34M$141M+ $0 short-term inv.$16M-$40M operating cash flowreport ↗
2024-Q1$56M$38M$106M+ $72M short-term inv.$33M-$59M operating cash flowreport ↗
2023-Q3$40M$61M$121M+ $130M short-term inv.$64M-$85M operating cash flowreport ↗
2023-Q2$44M$95M$153M+ $183M short-term inv.$88M-$111M operating cash flowreport ↗
2023-Q1$36M$74M$189M+ $167M short-term inv.$77M-$102M operating cash flowreport ↗
2022-Q3$16M$75M$156M+ $253M short-term inv.$92M-$52M operating cash flowreport ↗
2022-Q2$30M$71M$168M+ $270M short-term inv.$73M-$33M operating cash flowreport ↗
2022-Q1$61M$89M$186M+ $242M short-term inv.$63M-$8.5M operating cash flowreport ↗
2021-Q3$156M$76M$275M+ $212M short-term inv.—$44M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$6.4M$24M$48M+ $41M short-term inv.—-$4.8M operating cash flowreport ↗

Kyntra Bio reported full-year 2025 revenue of $6.44M, down 78.3% YoY, with R&D spend of $23.52M, down 75.4% YoY. Cash and equivalents were $47.87M, and the company reported net income of $183.45M for the year.

Management expects total cash, cash equivalents, investments, and accounts receivable of $109.4M to fund operations into 2028. The Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer is actively enrolling, with an interim analysis expected in the second half of 2026, and positive results from an investigator-sponsored study of FG-3246 combined with enzalutamide were presented at ASCO GU 2026. Kyntra Bio also submitted a pivotal Phase 3 protocol for roxadustat in lower-risk myelodysplastic syndromes and holds FDA Orphan Drug Designation for that program, with a goal of starting the Phase 3 trial in the second half of 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$30M$96M$50M+ $0 short-term inv.$12M-$138M operating cash flowreport ↗
2023-FY$148M$283M$114M+ $122M short-term inv.$71M-$315M operating cash flowreport ↗
2022-FY$141M$297M$156M+ $266M short-term inv.$73M-$146M operating cash flowreport ↗
2021-FY$235M$387M$171M+ $234M short-term inv.$73M-$82M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($40K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-15Wettig Thane · director, CEOAward / grant2,500$2.92$7KForm 4
2026-10-01Singer Andrew E. · directorAward / grant (derivative)14,000——Form 4
2026-09-06Wettig Thane · director, CEOTax withholding209$8.55$2KForm 4
2026-09-06DeLucia David · Chief Financial OfficerTax withholding22$8.55$188Form 4
2026-06-12Schoeneck James A · directorAward / grant (derivative)7,000——Form 4
2026-06-12Kauffman Michael · directorAward / grant (derivative)7,000——Form 4
2026-06-12EDWARDS JEFFREY L · directorAward / grant (derivative)7,000——Form 4
2026-06-12Ho Maykin · directorAward / grant (derivative)7,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 32 reporting institutions held 1.0M shares ($6.3M, 25.6% of shares outstanding).

#InstitutionSharesValue
1ARMISTICE CAPITAL, LLC400,000$2.7M
2VANGUARD CAPITAL MANAGEMENT LLC156,607$1.1M
3BlackRock, Inc.84,331$572K
4TWO SIGMA INVESTMENTS, LP49,511$336K
5GEODE CAPITAL MANAGEMENT, LLC45,998$312K
6HighTower Advisors, LLC39,744$269K
7UBS Group AG27,591$187K
8RENAISSANCE TECHNOLOGIES LLC27,481$186K
9VANGUARD FIDUCIARY TRUST CO23,942$162K
10Birchview Capital, LP22,566$153K
11STATE STREET CORP20,284$138K
12JANE STREET GROUP, LLC12,228$83K
13ADAR1 Capital Management, LLC10,469$71K
14GROUP ONE TRADING LLC4,492$30K
15Vanguard Global Advisers, LLC1,424$10K